Wednesday, June 18, 2014 10:19:05 AM
BMSN*Valuation(s), FDA, & Orphan Drug Thoughts…
Below is a compilation of my posts of which some of the info has been edited to add more clarity, but most of it is as I had originally posted over the past few weeks.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85160997
Significance of BMSN IND & Breast Cancer Treatment News…
Significant for understanding, read the post/link below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84957802
Below is some key info to help investors to understand the importance of this breast cancer treatment news (also looks like their drug will be used to treat prostate cancer too. Within this post, you will be able to see how this news ”potentially” positions BMSN to be able to make billions of dollars per year just from this breast cancer piece alone.
Please, don’t just believe me. Read through this post and do the math yourself.
Below are some links to confirm that there is basically around 220,000+ new cases of breast cancer in the US and 1,300,000+ new cases of breast cancer worldwide that are diagnosed. One could also Google this data to research to see that such is correctly and vastly considered:
http://www.cdc.gov/cancer/breast/statistics/
http://globocan.iarc.fr/factsheets/cancers/breast.asp
http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/
This is very significant and very powerful with understanding this recent news from BMSN’s wholly owned subsidiary Regen BioPharma, Inc. positioning itself to own the patented intellectual property covering a novel means of treating breast cancer by augmenting the immune system using a "gene silencing" approach.
As per the PR…
http://ih.advfn.com/p.php?pid=nmona&article=56463068
For inquiring minds, Dendreon Corp. trades under the ticker of DNDN on the NASDAQ GS at $5.40+ per share:
http://finance.yahoo.com/q?s=DNDN
If Dendreon’s cancer vaccine/medicine called Provenge that has already been approved by the FDA costs $93,000 per treatment and is considered the best thing out there now for fighting cancer and can generate Revenues of $240,000,000 for just three quarters, then BMSN’s technique for its own cancer medicine under their "gene silencing" approach that’s considered 100% times better can be sold for at least the same $93,000 per treatment or higher upon FDA approval in my opinion which could generate far more in Revenues.
As I had indicated above, there are basically around 220,000+ new cases of breast cancer in the US and 1,300,000+ new cases of breast cancer worldwide that are diagnosed.
Potential Annual Revenues within the US:
220,000 US New Cases x $93,000 per treatment = $20,460,000,000
Potential Annual Revenues within the World:
1,300,000 Worldwide New Cases x $93,000 per treatment = $120,900,000,000
With keeping things real, please understand that it is not likely that BMSN would treat everyone within the world although the potential to consider such exists. So I would not expect those numbers above although a few billion still would not be out of the question considering that their treatment would apply to a few other types of cancer treatments too.
A more conservative number would be to know that BMSN probably would only be able to treat somewhere in the area of 3,500 patients per year from researching the norm for some other companies on the major market in a fairly perfect world. This means that a more conservative number would be as indicated below…
Potential Annual Revenues from probable amount to receive cancer treatment:
3,500 Probable Amount Treated x $93,000 per treatment = $325,500,000
As you can see, this is in line with what some of the major market stocks/companies are generating from the sale of their treatments. Still, the potential is there to make well above that amount when you start considering treatment for prostate cancer and other cancers. There is roughly an 11% profit Margin for stocks within the Biotech Industry as indicated below:
http://biz.yahoo.com/p/515conameu.html
This makes the above amount of ”potential” Revenues from this breast cancer piece to be about $35,805,000 in Revenues for BMSN as derived below:
$325,000,000 x 11% Net Profit Margin = $35,805,000 in Net Profit/Income
Per the recent 8-K below, the BMSN Outstanding Shares (OS) is 1,035,911,549 shares:
http://www.sec.gov/Archives/edgar/data/1079282/000110262413000003/biomatrix8k.htm
Now consider the formulas below to derive a “potential” ”Fundamental Valuation” for BMSN from its breast cancer drug (the HemaXellerate I™ is a different drug and a valuation is explained further below within this post):
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
So…
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
$35,805,000 Net Profit/Income ÷ 1,035,911,549 OS = .0345 Earnings Per Share (EPS)
I will use the P/E Ratio for this breast cancer drug potential that I used in a previous valuation post for BMSN’s HemaXellerate I™ stem cell drug since it is far more conservative than the current P/E Ratio for the Biotech Industry.
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
.0345 EPS x 57.80 P/E Ratio = $1.99 per share
As stated from this news, which confirms the validity of their approach, this gene silencing therapy was developed through over 1.5 million dollars of grant funding at the University of Western Ontario, Canada. This approach offers the possibility of destroying tumors in a non-toxic manner through leveraging the body's own immune system to recognize the cancer as "foreign" and subsequently eradicating it.
http://ih.advfn.com/p.php?pid=nmona&article=56463068
BMSN & the Merk & Co. Connection…
As per Professor Min…
http://ih.advfn.com/p.php?pid=nmona&article=56463068
In my opinion, when BMSN added Dr. Wei-Ping Min to their Scientific Advisory Board, it linked BMSN to be in the eyes of Merk & Co. which trades on the NYSE:MRK at $42.00+ per share.
There is absolutely no way Dr. Wei-Ping Min would associate himself with BMSN unless he knew 100% that BMSN had something very worthy of note to be a part of supporting. Because of Dr. Wei-Ping Min’s credentials, if he believes that BMSN is not a scam and is very real, then I will truly trust his due diligence (DD) to do such too.
Dr. Wei-Ping Min is the inventor of siRNA therapeutics which was bought out by Merk & Co for $13.00 per share:
Below is confirmation of BMSN making such a move to add Dr. Wei-Ping Min to their Scientific Advisory Board:
Here’s a little bit more about Dr. Wei-Ping Min:
http://www.researchgate.net/publication/8440294_RNA_interference_a_potent_tool_for_gene-specific_therapeutics
[Suppressed Image]
More About Dr. Weiping Min, M.D. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85035901
http://regenbiopharma.com/advisory-board.html
[Suppressed Image][Suppressed Image]
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946297
cowboydancer, with these important BMSN thoughts…
These important BMSN thoughts you have posted are right in line with what I have confirmed from personally speaking with the FDA Office. The info below was taken directly from the FDA website and is what I was personally told by the FDA office…
Guidance for Industry Fast Track Drug Development Programs — Designation, Development, and Application Review
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079736.pdf
On Page 9
[Suppressed Image]
On Page 17…
[Suppressed Image]
[Suppressed Image][Suppressed Image][Suppressed Image]
Now everyone should read again an earlier post I made explaining my conversation with the FDA:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84909724
Again, as I had previously stated, please, do not use or consider such valuation post to be the gospel for where BMSN is going. Use it as a framework to have in your hip pocket to understand where BMSN could very well go ”just-in-case” BMSN deliver the goods. You will have to use the ”Substitution Property” to replace any variable that may change.
v/r
Sterling
[Suppressed Image][Suppressed Image]
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83394755
A Very Likely $1.19 BMSN Fundamental Valuation…
Before I explain how ”logically” BMSN could ”Fundamentally” be worth trading in the $1.19 per share area, I think it fair to first understand some of the key variables that I will use to help me to derive this ”Fundamental Valuation” for BMSN.
Look within the Yahoo link below and you will see that BMSN trades within the Biotechnology Industry that exists within the Healthcare Sector:
http://finance.yahoo.com/q/pr?s=bmsn
[Suppressed Image]
Within the Biotechnology Industry, stocks that are fully reporting and file with the SEC have a Net Profit Margin % of 11.90% and a Price to Earnings (P/E) Ratio of 57.80 as indicated within the Yahoo Finance database as confirmed below:
http://biz.yahoo.com/p/515conameu.html
[Suppressed Image]
Read the post below to fully understand the importance of the P/E Ratio:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57154170
Now consider below that it has been indicated that BMSN is seeking to enter into an $18 billion market for bone marrow stimulating growth factors as indicated below since beginning the development of its first clinical product (HemaXellerate™) which is a cellular drug designed to heal damaged bone marrow:
http://www.prweb.com/releases/2012/10/prweb9972993.htm
The question now is… Do you believe that BMSN would be able to achieve at least 1% of that $18 Billion market if they obtain their FDA Letter? The answers is… Yes, no doubt! However, for the purposes of this valuation, I will remain conservative and figure that BMSN would only be able to achieve obtaining only 1% of that $18 Billion market so that investors could understand the magnitude of the true potential that would then exist in BMSN…
1% of $18,000,000,000 = $180,000,000 in Revenues
$180,000,000 x 11.90% Net Profit Margin = $21,420,000 in Net Profit/Income
Per the recent 8-K below, the BMSN Outstanding Shares (OS) is 1,035,911,549 shares:
http://www.sec.gov/Archives/edgar/data/1079282/000110262413000003/biomatrix8k.htm
Now consider the formulas below to derive a “potential” ”Fundamental Valuation” for BMSN:
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
So…
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
$21,420,000 Net Profit/Income ÷ 1,035,911,549 OS = .0206 Earnings Per Share (EPS)
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
.0206 EPS x 57.80 P/E Ratio = $1.19 per share
This means that given the above fundamental variables, the expected price per share could be justified to be trading within the $1.19 per share range for BMSN if BMSN is only able to capture only 1% of its $18 Billion market of which it exists.
If you believe that BMSN would capture still an amount far less than 1% of the $18 Billion market to let’s say maybe ”half” of the 1% of the $18 Billion market, then the expected price per share could be justified trading within the .59 per share range for BMSN.
On the contrary, if you believe that BMSN is going to capture far more than 1% of the $18 Billion market, then for every 1% that you believe it would obtain from the $18 Billion market… then you can ”fundamentally” add $1.19 per share for each 1% of expectation. Example below:
1% of $18 Billion Market = $1.19 per share for BMSN
2% of $18 Billion Market = $2.38 per share for BMSN
3% of $18 Billion Market = $3.57 per share for BMSN
4% of $18 Billion Market = $4.76 per share for BMSN
5% of $18 Billion Market = $5.95 per share for BMSN
And so on… and so on… etc.
With this valuation post, it is like any other valuation post that I have made in that it will not be up to what I post or say in order for these price levels to be achieved. It will be up to the company to deliver the ”substance” that we all here are expecting to be the stimulus for such to transpire. Here with BMSN, that primary substance that should act as the stimulus would be the FDA Letter. If BMSN delivers the FDA Letter to the public, then it is very possible that any of the valuations above by themselves or combined could happen.
Please, do not use or consider this post to be the gospel for where BMSN is going. Use it as a framework to have to understand where BMSN could very well go ”just-in-case” BMSN deliver the goods.
Before closing, there is something else very important to note… BMSN trades on the OTCQB. This means that they are fully reporting and file their financials with the SEC. This also means that they have ”audited” financials already acclimated with its existence.
BMSN SEC Filings:
http://finance.yahoo.com/q/sec?s=BMSN+SEC+Filings
[Suppressed Image]
http://www.otcmarkets.com/stock/BMSN/company-info
http://www.otcmarkets.com/companies-advisors/otcqb
[Suppressed Image]
Bottom line, obtaining the FDA Letter is key, but of course it will also be important for BMSN to remain current and qualified on the OTCQB venture marketplace too. This means that BMSN is very legit and very transparent. The more investors learn of BMSN and its potential, the more significant growth that will be achieved for BMSN.
With BMSN, there are the following key things that investors are expecting to continue the move northward…
1**Filing of 10Q/K
2**Pending FDA IND Application News
3**Research & Safety Data News
4**Phase I & II Clinical Trial Update News
5**Merger News to bring even more valuation
BMSN Website:
http://www.bmsn.us/
v/r
Sterling
[Suppressed Image][Suppressed Image]
Each stock will do what it will do based on its own merit and not whether or not I post a valuation about it or not. There is absolutely no way you can stereotype the bad in one stock with different managements, different filings, etc. and try to believe that whatever outcome that transpired over there will happen over here with BMSN. To do such is totally foolish.
Since you want to compare BMSN to something, why not compare BMSN to one of the last Biotech stocks that I was in, VKNG, a while ago back when it was at .002 per share:
http://investorshub.advfn.com/boards/memberpoststoboard.aspx?userid=1551&boardid=10896
I "originally" mentioned VKNG at .002 per share (had to get .003 though & higher). Later, VKNG had gone to $1.10 per share. VKNG later stabilized in the .25+ per share area where later VKNG was bought out for .27 per share by CONMED Corporation which trades on the NASDAQ under the ticker CNMD at $28.00+ per share as indicated below:
http://ih.advfn.com/p.php?pid=nmona&article=54279009
My point, which is contrary to yours, is that you just never know as like with VKNG, BMSN do have a history of having ”audited” financials. I am not expecting much from the BMSN upcoming financials, but it is basically nothing more than a formality to maintain being current with their filings with the SEC since BMSN is fully reporting and trade on the OTCQB. I am expecting to see their financials released sometime after the market closes today at the latest.
BMSN is very different than the stocks of which you are referring. I am not saying that BMSN is going to be the next VKNG, but I am saying that you just never know. I do believe that BMSN has more potential than VKNG and since VKNG went to $1.10 without obtaining 1% of its market, BMSN could actually get to such level without ever obtaining that 1% from their market anytime soon. If BMSN obtains their FDA Letter, then the sky will be the limit. This will be when the stars will really begin to align.
v/r
Sterling
[Suppressed Image]
Sterling's Trading & Investing Strategies:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=390925
Below is a compilation of my posts of which some of the info has been edited to add more clarity, but most of it is as I had originally posted over the past few weeks.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85160997
Significance of BMSN IND & Breast Cancer Treatment News…
Significant for understanding, read the post/link below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84957802
Below is some key info to help investors to understand the importance of this breast cancer treatment news (also looks like their drug will be used to treat prostate cancer too. Within this post, you will be able to see how this news ”potentially” positions BMSN to be able to make billions of dollars per year just from this breast cancer piece alone.
Please, don’t just believe me. Read through this post and do the math yourself.
Below are some links to confirm that there is basically around 220,000+ new cases of breast cancer in the US and 1,300,000+ new cases of breast cancer worldwide that are diagnosed. One could also Google this data to research to see that such is correctly and vastly considered:
http://www.cdc.gov/cancer/breast/statistics/
http://globocan.iarc.fr/factsheets/cancers/breast.asp
http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/
This is very significant and very powerful with understanding this recent news from BMSN’s wholly owned subsidiary Regen BioPharma, Inc. positioning itself to own the patented intellectual property covering a novel means of treating breast cancer by augmenting the immune system using a "gene silencing" approach.
As per the PR…
http://ih.advfn.com/p.php?pid=nmona&article=56463068
For inquiring minds, Dendreon Corp. trades under the ticker of DNDN on the NASDAQ GS at $5.40+ per share:
http://finance.yahoo.com/q?s=DNDN
If Dendreon’s cancer vaccine/medicine called Provenge that has already been approved by the FDA costs $93,000 per treatment and is considered the best thing out there now for fighting cancer and can generate Revenues of $240,000,000 for just three quarters, then BMSN’s technique for its own cancer medicine under their "gene silencing" approach that’s considered 100% times better can be sold for at least the same $93,000 per treatment or higher upon FDA approval in my opinion which could generate far more in Revenues.
As I had indicated above, there are basically around 220,000+ new cases of breast cancer in the US and 1,300,000+ new cases of breast cancer worldwide that are diagnosed.
Potential Annual Revenues within the US:
220,000 US New Cases x $93,000 per treatment = $20,460,000,000
Potential Annual Revenues within the World:
1,300,000 Worldwide New Cases x $93,000 per treatment = $120,900,000,000
With keeping things real, please understand that it is not likely that BMSN would treat everyone within the world although the potential to consider such exists. So I would not expect those numbers above although a few billion still would not be out of the question considering that their treatment would apply to a few other types of cancer treatments too.
A more conservative number would be to know that BMSN probably would only be able to treat somewhere in the area of 3,500 patients per year from researching the norm for some other companies on the major market in a fairly perfect world. This means that a more conservative number would be as indicated below…
Potential Annual Revenues from probable amount to receive cancer treatment:
3,500 Probable Amount Treated x $93,000 per treatment = $325,500,000
As you can see, this is in line with what some of the major market stocks/companies are generating from the sale of their treatments. Still, the potential is there to make well above that amount when you start considering treatment for prostate cancer and other cancers. There is roughly an 11% profit Margin for stocks within the Biotech Industry as indicated below:
http://biz.yahoo.com/p/515conameu.html
This makes the above amount of ”potential” Revenues from this breast cancer piece to be about $35,805,000 in Revenues for BMSN as derived below:
$325,000,000 x 11% Net Profit Margin = $35,805,000 in Net Profit/Income
Per the recent 8-K below, the BMSN Outstanding Shares (OS) is 1,035,911,549 shares:
http://www.sec.gov/Archives/edgar/data/1079282/000110262413000003/biomatrix8k.htm
Now consider the formulas below to derive a “potential” ”Fundamental Valuation” for BMSN from its breast cancer drug (the HemaXellerate I™ is a different drug and a valuation is explained further below within this post):
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
So…
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
$35,805,000 Net Profit/Income ÷ 1,035,911,549 OS = .0345 Earnings Per Share (EPS)
I will use the P/E Ratio for this breast cancer drug potential that I used in a previous valuation post for BMSN’s HemaXellerate I™ stem cell drug since it is far more conservative than the current P/E Ratio for the Biotech Industry.
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
.0345 EPS x 57.80 P/E Ratio = $1.99 per share
As stated from this news, which confirms the validity of their approach, this gene silencing therapy was developed through over 1.5 million dollars of grant funding at the University of Western Ontario, Canada. This approach offers the possibility of destroying tumors in a non-toxic manner through leveraging the body's own immune system to recognize the cancer as "foreign" and subsequently eradicating it.
http://ih.advfn.com/p.php?pid=nmona&article=56463068
BMSN & the Merk & Co. Connection…
As per Professor Min…
http://ih.advfn.com/p.php?pid=nmona&article=56463068
In my opinion, when BMSN added Dr. Wei-Ping Min to their Scientific Advisory Board, it linked BMSN to be in the eyes of Merk & Co. which trades on the NYSE:MRK at $42.00+ per share.
There is absolutely no way Dr. Wei-Ping Min would associate himself with BMSN unless he knew 100% that BMSN had something very worthy of note to be a part of supporting. Because of Dr. Wei-Ping Min’s credentials, if he believes that BMSN is not a scam and is very real, then I will truly trust his due diligence (DD) to do such too.
Dr. Wei-Ping Min is the inventor of siRNA therapeutics which was bought out by Merk & Co for $13.00 per share:
Below is confirmation of BMSN making such a move to add Dr. Wei-Ping Min to their Scientific Advisory Board:
Here’s a little bit more about Dr. Wei-Ping Min:
http://www.researchgate.net/publication/8440294_RNA_interference_a_potent_tool_for_gene-specific_therapeutics
[Suppressed Image]
More About Dr. Weiping Min, M.D. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=85035901
http://regenbiopharma.com/advisory-board.html
[Suppressed Image][Suppressed Image]
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946297
cowboydancer, with these important BMSN thoughts…
These important BMSN thoughts you have posted are right in line with what I have confirmed from personally speaking with the FDA Office. The info below was taken directly from the FDA website and is what I was personally told by the FDA office…
Guidance for Industry Fast Track Drug Development Programs — Designation, Development, and Application Review
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM079736.pdf
On Page 9
[Suppressed Image]
On Page 17…
[Suppressed Image]
[Suppressed Image][Suppressed Image][Suppressed Image]
Now everyone should read again an earlier post I made explaining my conversation with the FDA:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84909724
Again, as I had previously stated, please, do not use or consider such valuation post to be the gospel for where BMSN is going. Use it as a framework to have in your hip pocket to understand where BMSN could very well go ”just-in-case” BMSN deliver the goods. You will have to use the ”Substitution Property” to replace any variable that may change.
v/r
Sterling
[Suppressed Image][Suppressed Image]
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83394755
A Very Likely $1.19 BMSN Fundamental Valuation…
Before I explain how ”logically” BMSN could ”Fundamentally” be worth trading in the $1.19 per share area, I think it fair to first understand some of the key variables that I will use to help me to derive this ”Fundamental Valuation” for BMSN.
Look within the Yahoo link below and you will see that BMSN trades within the Biotechnology Industry that exists within the Healthcare Sector:
http://finance.yahoo.com/q/pr?s=bmsn
[Suppressed Image]
Within the Biotechnology Industry, stocks that are fully reporting and file with the SEC have a Net Profit Margin % of 11.90% and a Price to Earnings (P/E) Ratio of 57.80 as indicated within the Yahoo Finance database as confirmed below:
http://biz.yahoo.com/p/515conameu.html
[Suppressed Image]
Read the post below to fully understand the importance of the P/E Ratio:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57154170
Now consider below that it has been indicated that BMSN is seeking to enter into an $18 billion market for bone marrow stimulating growth factors as indicated below since beginning the development of its first clinical product (HemaXellerate™) which is a cellular drug designed to heal damaged bone marrow:
http://www.prweb.com/releases/2012/10/prweb9972993.htm
The question now is… Do you believe that BMSN would be able to achieve at least 1% of that $18 Billion market if they obtain their FDA Letter? The answers is… Yes, no doubt! However, for the purposes of this valuation, I will remain conservative and figure that BMSN would only be able to achieve obtaining only 1% of that $18 Billion market so that investors could understand the magnitude of the true potential that would then exist in BMSN…
1% of $18,000,000,000 = $180,000,000 in Revenues
$180,000,000 x 11.90% Net Profit Margin = $21,420,000 in Net Profit/Income
Per the recent 8-K below, the BMSN Outstanding Shares (OS) is 1,035,911,549 shares:
http://www.sec.gov/Archives/edgar/data/1079282/000110262413000003/biomatrix8k.htm
Now consider the formulas below to derive a “potential” ”Fundamental Valuation” for BMSN:
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
So…
Net Profit/Income ÷ OS = Earnings Per Share (EPS)
$21,420,000 Net Profit/Income ÷ 1,035,911,549 OS = .0206 Earnings Per Share (EPS)
EPS x Price to Earnings (P/E) Ratio = Expected Price Per Share
.0206 EPS x 57.80 P/E Ratio = $1.19 per share
This means that given the above fundamental variables, the expected price per share could be justified to be trading within the $1.19 per share range for BMSN if BMSN is only able to capture only 1% of its $18 Billion market of which it exists.
If you believe that BMSN would capture still an amount far less than 1% of the $18 Billion market to let’s say maybe ”half” of the 1% of the $18 Billion market, then the expected price per share could be justified trading within the .59 per share range for BMSN.
On the contrary, if you believe that BMSN is going to capture far more than 1% of the $18 Billion market, then for every 1% that you believe it would obtain from the $18 Billion market… then you can ”fundamentally” add $1.19 per share for each 1% of expectation. Example below:
1% of $18 Billion Market = $1.19 per share for BMSN
2% of $18 Billion Market = $2.38 per share for BMSN
3% of $18 Billion Market = $3.57 per share for BMSN
4% of $18 Billion Market = $4.76 per share for BMSN
5% of $18 Billion Market = $5.95 per share for BMSN
And so on… and so on… etc.
With this valuation post, it is like any other valuation post that I have made in that it will not be up to what I post or say in order for these price levels to be achieved. It will be up to the company to deliver the ”substance” that we all here are expecting to be the stimulus for such to transpire. Here with BMSN, that primary substance that should act as the stimulus would be the FDA Letter. If BMSN delivers the FDA Letter to the public, then it is very possible that any of the valuations above by themselves or combined could happen.
Please, do not use or consider this post to be the gospel for where BMSN is going. Use it as a framework to have to understand where BMSN could very well go ”just-in-case” BMSN deliver the goods.
Before closing, there is something else very important to note… BMSN trades on the OTCQB. This means that they are fully reporting and file their financials with the SEC. This also means that they have ”audited” financials already acclimated with its existence.
BMSN SEC Filings:
http://finance.yahoo.com/q/sec?s=BMSN+SEC+Filings
[Suppressed Image]
http://www.otcmarkets.com/stock/BMSN/company-info
http://www.otcmarkets.com/companies-advisors/otcqb
[Suppressed Image]
Bottom line, obtaining the FDA Letter is key, but of course it will also be important for BMSN to remain current and qualified on the OTCQB venture marketplace too. This means that BMSN is very legit and very transparent. The more investors learn of BMSN and its potential, the more significant growth that will be achieved for BMSN.
With BMSN, there are the following key things that investors are expecting to continue the move northward…
1**Filing of 10Q/K
2**Pending FDA IND Application News
3**Research & Safety Data News
4**Phase I & II Clinical Trial Update News
5**Merger News to bring even more valuation
BMSN Website:
http://www.bmsn.us/
v/r
Sterling
[Suppressed Image][Suppressed Image]
Each stock will do what it will do based on its own merit and not whether or not I post a valuation about it or not. There is absolutely no way you can stereotype the bad in one stock with different managements, different filings, etc. and try to believe that whatever outcome that transpired over there will happen over here with BMSN. To do such is totally foolish.
Since you want to compare BMSN to something, why not compare BMSN to one of the last Biotech stocks that I was in, VKNG, a while ago back when it was at .002 per share:
http://investorshub.advfn.com/boards/memberpoststoboard.aspx?userid=1551&boardid=10896
I "originally" mentioned VKNG at .002 per share (had to get .003 though & higher). Later, VKNG had gone to $1.10 per share. VKNG later stabilized in the .25+ per share area where later VKNG was bought out for .27 per share by CONMED Corporation which trades on the NASDAQ under the ticker CNMD at $28.00+ per share as indicated below:
http://ih.advfn.com/p.php?pid=nmona&article=54279009
My point, which is contrary to yours, is that you just never know as like with VKNG, BMSN do have a history of having ”audited” financials. I am not expecting much from the BMSN upcoming financials, but it is basically nothing more than a formality to maintain being current with their filings with the SEC since BMSN is fully reporting and trade on the OTCQB. I am expecting to see their financials released sometime after the market closes today at the latest.
BMSN is very different than the stocks of which you are referring. I am not saying that BMSN is going to be the next VKNG, but I am saying that you just never know. I do believe that BMSN has more potential than VKNG and since VKNG went to $1.10 without obtaining 1% of its market, BMSN could actually get to such level without ever obtaining that 1% from their market anytime soon. If BMSN obtains their FDA Letter, then the sky will be the limit. This will be when the stars will really begin to align.
v/r
Sterling
[Suppressed Image]
Sterling's Trading & Investing Strategies:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=390925
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.